Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children

Update Il y a 4 ans
Reference: EUCTR2008-005791-27

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• To describe the safety profiles (injection site reactions and systemic events) during the 21 days following each vaccination in subjects receiving the D0-D21 and the D0-D42 vaccination schedules, and 14 days and 21 days after Vac1 and Vac2, respectively, in subjects aged 9 to 17 years receiving the D0-D14 vaccination schedule • To describe the immune response 21 days after each vaccination in subjects receiving the D0-D21 vaccination schedule


Inclusion criteria

  • Vaccination of healthy children aged 6 months to 17 years with pandemic Flu H5N1 vaccine (30µgHA+aluminum hydroxide vaccine)

Links